Pharmesis International (BFK) H1 2025 earnings summary

Executive summary

• H1 2025 revenue rose 13.9% YoY to RMB 27.202m; gross margin increased to 38.0% from 36.4%.

• Net loss narrowed to RMB 1.372m from RMB 4.014m; attributable net loss was reported as RMB 1.4m versus RMB 3.5m. The prior-year net loss included RMB 1.094m tax expense from earlier-period assessments.

Financial highlights

• Revenue was RMB 27.202m versus RMB 23.874m; gross profit rose to RMB 10.338m from RMB 8.697m.

• Operating loss narrowed to RMB 1.039m from RMB 2.569m.

• Selling and distribution costs fell 5.6% to RMB 5.275m; administrative costs rose 8.6% to RMB 6.206m, mainly on personnel expenses and expected-credit-loss allowance.

• Finance costs increased to RMB 359,000 from RMB 352,000, mainly due to higher interest expenses.

Outlook and guidance

• Digital marketing, e-commerce and sales-channel expansion aim to broaden customer reach, improve product accessibility and support revenue growth.

• Priorities include boosting sales, cautious operations, and prudent cost and cash-flow management; significant payment obligations over the next 12 months are expected to be met through improved sales and continued management.